T. Rowe Price Associates
HZNP

T. Rowe Price Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

T. Rowe Price Associates’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-129,492
Closed -$15M – 2968
2023
Q3 		$15M Sell
129,492
-205,184
-61% -$22M ﹤0.01% 985
2023
Q2 		$34.4M Sell
334,676
-145,327
-30% -$15.3M ﹤0.01% 811
2023
Q1 		$52.4M Sell
480,003
-155,052
-24% -$17.1M 0.01% 677
2022
Q4 		$72.3M Sell
635,055
-154,700
-20% -$12.8M 0.01% 565
2022
Q3 		$48.9M Sell
789,755
-1,616
-0.2% -$113K 0.01% 655
2022
Q2 		$63.1M Sell
791,371
-24,740
-3% -$2.34M 0.01% 809
2022
Q1 		$85.9M Sell
816,111
-28,106
-3% -$2.74M 0.01% 783
2021
Q4 		$91M Sell
844,217
-9,974
-1% -$1.09M 0.01% 794
2021
Q3 		$93.6M Sell
854,191
-55,275
-6% -$5.74M 0.01% 792
2021
Q2 		$85.2M Sell
909,466
-167,237
-16% -$15.4M 0.01% 845
2021
Q1 		$99.1M Sell
1,076,703
-89,343
-8% -$7.54M 0.01% 782
2020
Q4 		$85.3M Sell
1,166,046
-828,040
-42% -$61.5M 0.01% 783
2020
Q3 		$155M Sell
1,994,086
-1,172,812
-37% -$80.7M 0.02% 544
2020
Q2 		$176M Buy
3,166,898
+1,265,351
+67% +$54.1M 0.02% 500
2020
Q1 		$56.3M Buy
1,901,547
+55,745
+3% +$1.89M 0.01% 746
2019
Q4 		$66.8M Buy
1,845,802
+230,772
+14% +$7.08M 0.01% 798
2019
Q3 		$44M Buy
1,615,030
+513,282
+47% +$13.3M 0.01% 915
2019
Q2 		$26.5M Buy
1,101,748
+1,042,969
+1,774% +$26.5M ﹤0.01% 1098
2019
Q1 		$1.55M Buy
58,779
+765
+1% +$18.1K ﹤0.01% 1671
2018
Q4 		$1.13M Buy
58,014
+380
+0.7% +$7.45K ﹤0.01% 1747
2018
Q3 		$1.13M Sell
57,634
-613
-1% -$11.7K ﹤0.01% 1834
2018
Q2 		$965K Buy
58,247
+666
+1% +$10.2K ﹤0.01% 1856
2018
Q1 		$818K Buy
57,581
+468
+0.8% +$6.91K ﹤0.01% 1872
2017
Q4 		$834K Sell
57,113
-23,635
-29% -$332K ﹤0.01% 1874
2017
Q3 		$1.02M Sell
80,748
-123,170
-60% -$1.57M ﹤0.01% 1806
2017
Q2 		$2.42M Sell
203,918
-333,002
-62% -$4.14M ﹤0.01% 1517
2017
Q1 		$7.94M Buy
536,920
+14,700
+3% +$238K ﹤0.01% 1371
2016
Q4 		$8.45M Buy
522,220
+13,200
+3% +$239K ﹤0.01% 1347
2016
Q3 		$9.23M Buy
509,020
+16,535
+3% +$323K ﹤0.01% 1332
2016
Q2 		$8.11M Sell
492,485
-10,797
-2% -$175K ﹤0.01% 1325
2016
Q1 		$8.34M Buy
503,282
+10,600
+2% +$185K ﹤0.01% 1307
2015
Q4 		$10.7M Sell
492,682
-26,220
-5% -$510K ﹤0.01% 1266
2015
Q3 		$10.3M Sell
518,902
-497,487
-49% -$15.7M ﹤0.01% 1301
2015
Q2 		$35.3M Buy
1,016,389
+154,389
+18% +$4.71M 0.01% 958
2015
Q1 		$22.4M Sell
862,000
-4,700
-0.5% -$86.2K ﹤0.01% 1092
2014
Q4 		$11.2M Sell
866,700
-17,400
-2% -$218K ﹤0.01% 1297
2014
Q3 		$10.9M Sell
884,100
-5,900
-0.7% -$68.6K ﹤0.01% 1284
2014
Q2 		$14.1M Sell
890,000
-12,400
-1% -$177K ﹤0.01% 1229
2014
Q1 		$13.6M Buy
902,400
+876,400
+3,371% +$9.9M ﹤0.01% 1219
2013
Q4 		$198K Buy
+26,000
New +$140K ﹤0.01% 2317

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's HZNP Position: Q4 2023 in Review

T. Rowe Price Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 129,492 shares — an estimated $15M sold.

T. Rowe Price Associates first reported a position in HZNP in Q4 2013 and held it in 40 quarters. The position peaked at $176M in Q2 2020. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • T. Rowe Price Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 129,492 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $15M.
  • T. Rowe Price Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 40 quarters.
  • T. Rowe Price Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $176M in Q2 2020.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.